Quantinno Capital Management LP Has $352,000 Position in Organon & Co. (NYSE:OGN)

Quantinno Capital Management LP lifted its position in shares of Organon & Co. (NYSE:OGN) by 65.1% in the third quarter, HoldingsChannel.com reports. The fund owned 18,385 shares of the company’s stock after buying an additional 7,252 shares during the period. Quantinno Capital Management LP’s holdings in Organon & Co. were worth $352,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Prospera Private Wealth LLC bought a new stake in Organon & Co. during the third quarter worth $25,000. William B. Walkup & Associates Inc. acquired a new position in shares of Organon & Co. during the 2nd quarter worth $31,000. Abich Financial Wealth Management LLC lifted its position in shares of Organon & Co. by 5,646.3% during the 3rd quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock worth $45,000 after buying an additional 2,315 shares during the last quarter. Atlas Capital Advisors LLC boosted its stake in Organon & Co. by 2,236.5% in the second quarter. Atlas Capital Advisors LLC now owns 2,243 shares of the company’s stock valued at $46,000 after buying an additional 2,147 shares in the last quarter. Finally, Trust Co. of Vermont grew its position in Organon & Co. by 109.4% in the third quarter. Trust Co. of Vermont now owns 2,626 shares of the company’s stock valued at $50,000 after acquiring an additional 1,372 shares during the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on OGN. JPMorgan Chase & Co. cut shares of Organon & Co. from a “neutral” rating to an “underweight” rating and increased their target price for the stock from $18.00 to $20.00 in a report on Friday, September 6th. Evercore ISI raised shares of Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th.

Organon & Co. Stock Performance

Shares of OGN stock opened at $15.30 on Monday. The firm has a market capitalization of $3.94 billion, a price-to-earnings ratio of 3.04, a PEG ratio of 0.73 and a beta of 0.75. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The business’s 50-day moving average price is $16.46 and its 200-day moving average price is $19.17. Organon & Co. has a 12 month low of $12.62 and a 12 month high of $23.10.

Organon & Co. (NYSE:OGN) last posted its earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The business had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same quarter in the prior year, the business earned $0.78 earnings per share. The firm’s quarterly revenue was up 4.1% on a year-over-year basis. Equities research analysts forecast that Organon & Co. will post 3.89 EPS for the current year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Tuesday, November 12th were issued a $0.28 dividend. The ex-dividend date was Tuesday, November 12th. This represents a $1.12 dividend on an annualized basis and a yield of 7.32%. Organon & Co.’s payout ratio is 22.22%.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.